title: Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial.
authors.affiliation: Department of Psychiatry, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona, Ctra de Canyet s/n, 08916 Badalona, Spain. cdiezquevedo.germanstrias@gencat.cat
authors.forename: Crisanto
authors.initials: C
authors.lastname: Diez-Quevedo
authors.forename: Helena
authors.initials: H
authors.lastname: Masnou
authors.forename: Ramon
authors.initials: R
authors.lastname: Planas
authors.forename: Pere
authors.initials: P
authors.lastname: Castellví
authors.forename: Dolors
authors.initials: D
authors.lastname: Giménez
authors.forename: Rosa M
authors.initials: RM
authors.lastname: Morillas
authors.forename: Rocío
authors.initials: R
authors.lastname: Martín-Santos
authors.forename: Ricard
authors.initials: R
authors.lastname: Navinés
authors.forename: Ricard
authors.initials: R
authors.lastname: Solà
authors.forename: Pilar
authors.initials: P
authors.lastname: Giner
authors.forename: Mercè
authors.initials: M
authors.lastname: Ardèvol
authors.forename: Joan
authors.initials: J
authors.lastname: Costa
authors.forename: Moisés
authors.initials: M
authors.lastname: Diago
authors.forename: Juan
authors.initials: J
authors.lastname: Pretel
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015283:Citalopram / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000139:chemically induced* / Q000517:prevention & control; D004311:Double-Blind Method; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015283:Citalopram; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a